Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
The New York Proton Center
Eastern Cooperative Oncology Group
Hoffmann-La Roche
Neonc Technologies, Inc.
Eli Lilly and Company
Thomas Jefferson University
Thomas Jefferson University
UNICANCER
National Cancer Institute (NCI)
Mayo Clinic
University of Illinois at Chicago
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Yale University
National Cancer Institute (NCI)
Duke University
Children's Oncology Group
National Cancer Institute (NCI)